Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment

Table 3 Available vaccines

	Company	Antigen - Adjuvant	Posology	Dosing
Engerix-B®	GlaxoSmithKline	Rec. major S Ag (yeast) Aluminum	1 mL	3- or 4-dose
			20 mcg	0-1-6 mo
				0-7 d-21 d-12 mo
HBVaxPRO®	Sanofi-Pasteur MSD	Rec. major S Ag (yeast) Aluminum	1 mL	3- or 4-dose
			5 mcg	0-1-6 mo
			10 mcg	0-1-2-12 mo
			40 mcg
Fendrix®	GlaxoSmithKline	Rec. major S Ag (yeast) Aluminum + 3-O-desacyl-4 - monophosphoryl lipid A	0.5 mL	4-dose
			20 mcg	0-1-2-6 mo
Heplisav-B®	Dynavax	Rec. major S Ag (yeast) HepB-CpG ligand	0.5 mL	2-dose
			20 mcg	0-1 mo
Twinrix®	GlaxoSmithKline	In.HAV + Rec. major S Ag (yeast) Aluminum	1 mL	3-dose
			720/20 mcg	0-7-21 d
				0-1-6 mo
Sci-B-Vac®	VBI Vaccines	Major S Ag, minor pre-S1 + pre-S2 Ag (mammalian cell) Aluminum	1 mL	3-dose
			10 mcg	0-1-6 mo
Pediarix®	GlaxoSmithKline	DTaP + inactivated poliovirus + Rec.S (yeast) Aluminum	0.5 Ml	3-dose
			10 mcg	(6-8 wk interval)

Ag: Antigen; DTaP: Diphtheria-tetanus-whooping cough (pertussis); In.HAV: Inactivated hepatitis A virus; Rec.: Recombinant.